miércoles, 12 de mayo de 2010

Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)


U.S. Food and Drug Administration

Office of Special Health Issues
10903 New Hampshire Avenue
Silver Spring, MD 20993
Phone: 301-796-8460

Dear Colleague:
The U.S. Food and Drug Administration (FDA) today launched a program designed to educate health care providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.
The Bad Ad Program is an FDA-sponsored educational outreach effort administered by the agency’s Division of Drug Marketing, Advertising, and Communications (DDMAC), in the FDA’s Center for Drug Evaluation and Research.
Attached is a letter from Margaret Hamburg, M.D., Commissioner of Food and Drugs announcing the launch of this new program.
Additional information on the Bad Ad Program is available on FDA's website at http://www.fda.gov/badad.

Sincerely,
Janelle Derbis, PharmD
Health Programs Coordinator
Office of Special Health Issues
Food and Drug Administration
Janelle.Derbis@fda.hhs.gov

Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)
The Prescriber's Role -- Recognize and Report


FDA's educational outreach program is designed to educate healthcare providers about the role they can play in helping the agency make sure that prescription drug advertising and promotion is truthful and not misleading.

The "Bad Ad" Program is administered by the agency’s Division of Drug Marketing, Advertising, and Communications in the Center for Drug Evaluation and Research. It will help healthcare providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency.

Content on this Page

What You Can Do: Recognize & Report

Examples of Violations

Frequently Asked Questions

Recognize & Report: Contact Information

Division of Drug Marketing, Advertising, and Communications' (DDMAC) Mission


OPEN HERE PLEASE:
Truthful Prescription Drug Advertising and Promotion (Bad Ad Program)

No hay comentarios: